PDF herunterladen
Thromb Haemost 2006; 95(03): 585-586
DOI: 10.1160/TH05-09-0620
Letters to the Editor
Schattauer GmbH

Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasmaTAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD)

José Verdú
1   Sección de Hemostasia y Trombosis, Hospital General Universitario de Alicante, Alicante, Spain
,
Pascual Marco
1   Sección de Hemostasia y Trombosis, Hospital General Universitario de Alicante, Alicante, Spain
,
Susana Benlloch
2   Unidad de Investigatión, Hospital General Universitario de Alicante, Alicante, Spain
,
José Sanchez
2   Unidad de Investigatión, Hospital General Universitario de Alicante, Alicante, Spain
,
Javier Lucas
1   Sección de Hemostasia y Trombosis, Hospital General Universitario de Alicante, Alicante, Spain
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 15. September 2005

Accepted after resubmission 05. Januar 2006

Publikationsdatum:
29. November 2017 (online)

    Lizenzen und Reprints

 

 

  • References

  • 1 Frere C, Morange PE, Saut N. et al. Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. Thromb Haemost 2005; 94: 373-9.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 2 Henry M, Aubert H, Morange PE. et al. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97: 2053-8.
    CrossrefPubMedGoogle Scholar
  • 3 Brouwers GJ, Vos HL, Leebeek FW. et al. A novel possibly functional, single nucleotide polymorphism in the codingregionofthethrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001; 98: 1992-3.
    CrossrefPubMedGoogle Scholar
  • 4 Guimaraes AH, van Tilburg NH, Vos HL. et al. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 2004; 124: 659-65.
    CrossrefPubMedGoogle Scholar
  • 5 van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
    PubMedGoogle Scholar
  • 6 Juhan-Vague I, Morange PE, Aubert H. et al. HIF-MECH Study Group. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002; 22: 867-73.
    CrossrefPubMedGoogle Scholar
  • 7 Tregouet DA, Aubert H, Henry M. et al. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphisms. Hum Genet 2001; 109: 191-7.
    CrossrefPubMedGoogle Scholar
  • 8 Leebeek FW, Goor MP, Guimaraes AH. et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005; 03: 2211-8.
    CrossrefPubMedGoogle Scholar
  • 9 Eichinger S, Schonauer V, Weltermann A. et al. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004; 103: 3773-6.
    CrossrefPubMedGoogle Scholar
  • 10 Van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
    PubMedGoogle Scholar
  • 11 Gils A, Alessi MC, Brouwers E. et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122-7.
    CrossrefPubMedGoogle Scholar